You are here: Urology Textbook > Drugs in Urology > Dutasteride
Dutasteride: Treatment of Benign Prostate Hyperplasia
Mechanism of Action of Dutasteride
Dutasteride is a selective competitive inhibitor of 5α-reductase type 1 and 2 of the prostate, seminal vesicles and skin. The inhibition lowers the concentration of dihydrotestosterone (DHT) in the prostate. Since DHT causes the androgenic effect in the prostate, the inhibition of 5α-reductase leads to a reduction in prostate volume. Furthermore, dutasteride is used to treat male pattern baldness.
Indications for Dutasteride in Urology
Dutasteride is indicated in lower urinary tract symptoms or bleeding due to benign prostate enlargement.
Pharmacokinetics of Dutasteride
Side Effects of Dutasteride
- Reduction of PSA by 50%
- Decreased libido (4%)
- Decreased ejaculate volume
- Gynecomastia (1%)
- Erectile dysfunction (6%)
Drug Interactions with Dutasteride
No important drug interactions are known.
Contraindications of Dutasteride
- Hepatic insufficiency
- Women, pregnancy, children
Dosage of Dutasteride
0,5 mg 1–0–0 p.o.
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
- Andriole u.a. 2004 ANDRIOLE, G. ; BRUCHOVSKY, N. ; CHUNG, L. W. ; MATSUMOTO, A. M. ; RITTMASTER, R. ; ROEHRBORN, C. ; RUSSELL, D. ; TINDALL, D.:
- Dihydrotestosterone and the prostate: the scientific rationale for
5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
In: J Urol
172 (2004), Nr. 4 Pt 1, S. 1399–403
- Chapple 2004 CHAPPLE, C. R.:
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
Deutsche Version: Dutasterid